[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/16, MON) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 서밋, PD-1xVEGF '이보네스시맙' 폐암 "FDA 허가거절"
[https://www.biospectator.com/news/view/30411](https://www.biospectator.com/news/view/30411)

 유한양행, '자체발굴' CKD 후보물질 "1상 IND 승인" 
[https://m.biospectator.com/view/news_view.php?varAtcId=30409](https://m.biospectator.com/view/news_view.php?varAtcId=30409)

 HLB테라퓨틱스, 'Tβ4' 각막염 美3상 "1차 미충족"
[https://m.biospectator.com/view/news_view.php?varAtcId=30413](https://m.biospectator.com/view/news_view.php?varAtcId=30413)

 알테오젠, 초장기 '월1회 비만' 융합단백질 "첫 발표" 
[https://www.biospectator.com/news/view/30412](https://www.biospectator.com/news/view/30412)

 씨어스, UAE 버질홀딩스 최대주주와 스마트병동 MOU
[https://www.biospectator.com/news/view/30418](https://www.biospectator.com/news/view/30418)

 화이자 "사활", '1개월 GLP-1' 블랙스톤서 15억弗 조달 
[https://www.biospectator.com/news/view/30396](https://www.biospectator.com/news/view/30396)

 보어, '또' 中레미젠 'BAFF/APRIL 저해제' 3.56억弗 L/I  
[https://www.biospectator.com/news/view/30398](https://www.biospectator.com/news/view/30398)

 대원제약, '펠루비' 시럽제 소아 2상 "국내 IND 승인" 
[https://www.biospectator.com/news/view/30421](https://www.biospectator.com/news/view/30421)

 차바이오텍, 3Q 누적 매출 9016억 "전년比 2% 감소"
[https://www.biospectator.com/news/view/30420](https://www.biospectator.com/news/view/30420)

 노보, '카그리세마' 비만3상 저용량서 “체중 21% 감소” 
[https://www.biospectator.com/news/view/30417](https://www.biospectator.com/news/view/30417)

 키베르나, 1상 ‘차세대 CD19 CAR-T’ 우선순위 “낮춰”
[https://www.biospectator.com/news/view/30397](https://www.biospectator.com/news/view/30397)

 온코닉, 3Q 매출 170억 "전년比 11.5% 감소"
[https://www.biospectator.com/news/view/30424](https://www.biospectator.com/news/view/30424)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/16, MON) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)